Restulex

Bufo Rana, Causticum, Chamomilla, Crotalus Horridus, Digitalis Purpurea, Lachesis Mutus, Lilium Tigrinum, Pulsatilla (pratensis) Rhus Tox, Sulphur, Tarentula Hispana, Viscum Album, Zincum Metallicum.


Hellolife, Inc.
Human Otc Drug
NDC 49726-047
Restulex also known as Bufo Rana, Causticum, Chamomilla, Crotalus Horridus, Digitalis Purpurea, Lachesis Mutus, Lilium Tigrinum, Pulsatilla (pratensis) Rhus Tox, Sulphur, Tarentula Hispana, Viscum Album, Zincum Metallicum. is a human otc drug labeled by 'Hellolife, Inc.'. National Drug Code (NDC) number for Restulex is 49726-047. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Restulex drug includes Anemone Pratensis - 10 [hp_X]/1 Bufo Bufo Cutaneous Gland - 10 [hp_X]/1 Causticum - 10 [hp_X]/1 Crotalus Horridus Horridus Venom - 10 [hp_X]/1 Digitalis - 10 [hp_X]/1 Lachesis Muta Venom - 10 [hp_X]/1 Lilium Lancifolium Whole Flowering - 10 [hp_X]/1 Lycosa Tarantula - 10 [hp_X]/1 Matricaria Chamomilla - 10 [hp_X]/1 Sulfur - 10 [hp_X]/1 and more. The currest status of Restulex drug is Active.

Drug Information:

Drug NDC: 49726-047
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Restulex
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Bufo Rana, Causticum, Chamomilla, Crotalus Horridus, Digitalis Purpurea, Lachesis Mutus, Lilium Tigrinum, Pulsatilla (pratensis) Rhus Tox, Sulphur, Tarentula Hispana, Viscum Album, Zincum Metallicum.
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Hellolife, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ANEMONE PRATENSIS - 10 [hp_X]/1
BUFO BUFO CUTANEOUS GLAND - 10 [hp_X]/1
CAUSTICUM - 10 [hp_X]/1
CROTALUS HORRIDUS HORRIDUS VENOM - 10 [hp_X]/1
DIGITALIS - 10 [hp_X]/1
LACHESIS MUTA VENOM - 10 [hp_X]/1
LILIUM LANCIFOLIUM WHOLE FLOWERING - 10 [hp_X]/1
LYCOSA TARANTULA - 10 [hp_X]/1
MATRICARIA CHAMOMILLA - 10 [hp_X]/1
SULFUR - 10 [hp_X]/1
TOXICODENDRON PUBESCENS LEAF - 10 [hp_X]/1
VISCUM ALBUM FRUIT - 10 [hp_X]/1
ZINC - 10 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 10 Oct, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 05 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:HelloLife, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:8E272251DI
Q59QU6N72Q
DD5FO1WKFU
YHA2XLJ956
F1T8QT9U8B
VSW71SS07I
X67Z2963PI
86M454L2TT
G0R4UBI2ZZ
70FD1KFU70
6IO182RP7A
P83EQ521R3
J41CSQ7QDS
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
49726-047-6060 TABLET in 1 BOTTLE, PLASTIC (49726-047-60)10 Oct, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Indications for use: for the temporary relief of symptoms such as: • twitching • burning • heaviness • jerking • cramping • pain product indications are based solely on homeopathic materia medica and have not been evaluated by the fda.

Product Elements:

Restulex bufo rana, causticum, chamomilla, crotalus horridus, digitalis purpurea, lachesis mutus, lilium tigrinum, pulsatilla (pratensis) rhus tox, sulphur, tarentula hispana, viscum album, zincum metallicum. copovidone k25-31 crospovidone lactose monohydrate magnesium stearate mannitol microcrystalline cellulose silicon dioxide sorbitol bufo bufo cutaneous gland bufo bufo cutaneous gland causticum causticum matricaria chamomilla matricaria chamomilla crotalus horridus horridus venom crotalus horridus horridus venom digitalis digitalis lachesis muta venom lachesis muta venom lilium lancifolium whole flowering lilium lancifolium whole flowering anemone pratensis anemone pratensis toxicodendron pubescens leaf toxicodendron pubescens leaf sulfur sulfur lycosa tarantula lycosa tarantula viscum album fruit viscum album fruit zinc zinc h

Indications and Usage:

Indications for use: for the temporary relief of symptoms such as: • twitching • burning • heaviness • jerking • cramping • pain product indications are based solely on homeopathic materia medica and have not been evaluated by the fda.

Warnings:

Warnings: stop use and as a doctor if symptoms persist or worsen. if pregnant or breast-feeding, ask health professional before use. do not use if tamper seal is broken.

Dosage and Administration:

Directions: dissolve under tongue. 30-50lb (13.6kg-22.6kg): twice daily. 50lb+ (22.6kg): 1 tablet twice daily.

Package Label Principal Display Panel:

Package label display: ndc 49726-047-60 restulex tablets natural relief for restless leg symptoms homeopathic (otc) medicine 60 quick-dissolving tablets restulex

Further Questions:

Questions: dist. by: hellolife, inc. 4635 40th st se grand rapids, mi 49512 www.hellolife.net


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.